Clinical trials: Moderately to Severely Active Rheumatoid Arthritis, active
Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis
Korean Post-marketing Surveillance for Xeljanz XR
Xeljanz XR extended-release tablets 11 mg (Tofacitinib citrate) is a drug subject to the risk management plan in accordance with Article 4-1-11 of the "Regulation on Safety of Medicinal Products, etc." in Korea.
- Conditions
- Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis
- Trial name
- XRPMS (NCT04876781)
- Testing
- Tofacitinib XR
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Pfizer
Rheumatoid Arthrits
A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis
This study is to evaluate the efficacy and safety of different doses of proximod in moderate-to-severe active rheumatoid arthritis subjects with inadequate response or intolerance to bDMARDs and/or tsDMARDs
- Trial name
- NCT07856511
- Testing
- Proximod
- Volunteers
- 590 people
- Sponsor
- Jiankuan (Suzhou) Biotechnology Company Limited
Rheumatoid Arthritis
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.
- Trial name
- LaunchPAD-RA (NCT07276581)
- Testing
- AZD1163
- Where
- 147 sites in United States, Argentina and 15 more
- Volunteers
- 320 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for…
- Trial name
- NCT06972446
- Testing
- Lutikizumab, Ravagalimab
- Where
- 96 sites in United States, Canada and 10 more
- Volunteers
- 180 people
- Sponsor
- AbbVie
Rheumatoid Arthritis, Major Adverse Cardiac Events
Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL
The rationale of our study is to observe the incidence of MACE in RA patients treated with tofacitinib along with statins with one or more cardiovascular disease risks.
- Trial name
- TOFSTAT (NCT07554820)
- Testing
- Tofacitinib 5 MG
- Where
- Pakistan
- Volunteers
- 120 people
- Sponsor
- Shaikh Zayed Hospital, Lahore
Rheumatoid Arthritis (RA)
The Clinical Study on the Treatment of Refractory RA With UTAA91 Injection
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study.
- Trial name
- NCT07001956
- Testing
- UTAA91 injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Rheumatoid Arthritis (RA)
Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis
The goal of this study is to evaluate the safety, pharmacokinetic (PK) characteristics, and preliminary efficacy of a new oral chemical drug in : adults aged 18-70 years (male or female) with moderate to severe active rheumatoid…
- Trial name
- NCT07408024
- Testing
- TollB-001
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Toll Biotech Co. Ltd. (Beijing)
Rheumatoid Arthritis (RA), Anti IL-6R
Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis
A multicenter, randomized, double-blind, placebo-controlled, and active drug-controlled Phase III pivotal clinical trial of recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) for the…
- Trial name
- NCT06726096
- Testing
- Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 615 people
- Sponsor
- Beijing VDJBio Co., LTD.
Rheumatoid Arthritis (RA)
Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study.
- Trial name
- NCT06982547
- Testing
- UTAA91 injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Rheumatoid Arthritis
Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD
This is a multicenter, randomized, double-blind, parallel, placebo- and active comparator- controlled clinical study conducted in patients with moderately to severely active RA and an inadequate response to at least one DMARD…
- Trial name
- NCT07423533
- Testing
- GenSci120 150 mg, GenSci120 600 mg, GenSci120 1000 mg
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Sjögren, Sjogren Disease
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.
- Conditions
- Sjögren, Sjogren Disease, Sjogren's Syndrome
- Trial name
- NCT07041099
- Testing
- CLN-978
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 36 people
- Sponsor
- Cullinan Therapeutics Inc.
Moderate to Severe Active Rheumatoid Arthritis
A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis
This study is ongoing to explore the efficacy and safety of different strengths of SHR-3045 injection in moderate to severe active rheumatoid arthritis.
- Trial name
- NCT07233655
- Testing
- SHR-3045 Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Sjögren's Syndrome (SS)
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
Primary Objective: To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state Secondary Objectives: 1.
- Trial name
- NCT06245408
- Testing
- Dazodalibep
- Where
- 194 sites in United States, Argentina and 24 more
- Volunteers
- 434 people
- Sponsor
- Amgen
Rheumatoid Arthritis (RA)
TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs
This is a randomized, double-blind, placebo-controlled parallel-group Phase II study. The study aims to evaluate the efficacy and safety of TLL-018 in adult patients with moderate to severe active rheumatoid arthritis who have…
- Trial name
- NCT07748728
- Testing
- TLL-018
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Rheumatoid Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to…
- Trial name
- SELECT-COMPARE (NCT02629159)
- Testing
- Adalimumab, Upadacitinib
- Where
- 370 sites in United States, Argentina and 42 more
- Volunteers
- 1,629 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis
An observational study to describe the effectiveness, safety, and patient-reported outcomes in patients with moderate to severe active rheumatoid arthritis (RA) receiving filgotinib in real-world setting.
- Trial name
- FILOSOPHY (NCT04871919)
- Testing
- Filgotinib
- Where
- 89 sites in Belgium, Germany and 4 more
- Volunteers
- 1,304 people
- Sponsor
- Alfasigma S.p.A.
Rheumatoid Arthritis
Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the joints, causing pain, swelling, stiffness, and loss of function.
- Trial name
- NCT07904754
- Testing
- ABBV-722, Upadacitinib
- Volunteers
- 250 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis
This is a double-blind, randomized, placebo- and active-controlled study investigating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) doses of LFD-200.
- Trial name
- NCT07207954
- Testing
- LFD-200, Oral Prednisone
- Where
- 10 sites in Australia, Georgia and 3 more
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Lifordi Immunotherapeutics, Inc.
Rheumatoid Arthritis, Psoriatic Arthritis
A Study of SPY072 in Rheumatic Disease
This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases
- Trial name
- SKYWAY-RD (NCT07148414)
- Testing
- SPY002-072
- Where
- 64 sites in United States, Bulgaria and 6 more
- Volunteers
- 285 people
- Sponsor
- Spyre Therapeutics, Inc.
Rheumatoid Arthritis
A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)
Brief Summary: This is a randomized, double-blind study comparing LNK01001 to placebo in Chinese participants with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic…
- Trial name
- NCT06276998
- Testing
- LNK01001
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd